Thank you. On the subject of the PMPRB, as the member knows, we have already delayed the coming into force a number of times as a result of the stress on the industry but also their incredible focus on responding to COVID-19. We continue to have those conversations with all stakeholders, including the pharmaceutical companies, and we'll assess closer to the date how we proceed.
I will just say this: We will continue on our path to lower the cost of drugs in Canada for Canadians as well. This is an important aspect of PMPRB renewal and adjustments, and we have to stay focused on the fact that Canada pays some of the highest prices for drugs in the world. It is also critically important to Canada that we find a way to reduce those costs so that all Canadians can have access to medications that save lives.